Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E

This article was originally published in The Tan Sheet

Executive Summary

Health claim proposed to FDA July 12 by Durk Pearson, Sandy Shaw, Julian Whitaker, MD, the American Preventive Medical Association and Pure Encapsulations. The claim states: "As part of a healthy diet low in saturated fat and cholesterol, 400 IU/day of vitamin E...may reduce the risk of heart disease. Individuals who take anticoagulant medicine(s) should consult their physician before taking supplemental vitamin E." The filing follows the submission of three other health claims by the group for psyllium, saw palmetto and folic acid (1"The Tan Sheet" May 24, p. 15). Filing of the vitamin E claim was delayed pending supportive data. Although FDA originally denied the claims, a federal appeals court ruled Jan. 15 the agency should consider allowing health claims with labeled disclaimers

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel